MX2017014319A - Sal sodica de inhibidor de transportador de acido urico y su forma cristalina. - Google Patents
Sal sodica de inhibidor de transportador de acido urico y su forma cristalina.Info
- Publication number
- MX2017014319A MX2017014319A MX2017014319A MX2017014319A MX2017014319A MX 2017014319 A MX2017014319 A MX 2017014319A MX 2017014319 A MX2017014319 A MX 2017014319A MX 2017014319 A MX2017014319 A MX 2017014319A MX 2017014319 A MX2017014319 A MX 2017014319A
- Authority
- MX
- Mexico
- Prior art keywords
- sodium salt
- uric acid
- acid transporter
- present
- crystalline form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
La presente invención se relaciona con una sal sódica de un inhibidor de transportador de ácido úrico y la forma cristalina del mismo. En particular, la presente invención se relaciona con la sal sódica de un inhibidor de transportador de ácido úrico (URAT1), el cristal tipo I y el método de preparación del mismo. La presente invención se relaciona con formato de 1-((6-bromo-quinolin-4-il)tio)ciclobutil de sodio (el compuesto de fórmula (I)), y el cristal tipo I y su método de preparación. El cristal tipo I del compuesto de fórmula (I) obtenido en la presente invención tiene buena estabilidad de forma de cristal y estabilidad química, y el solvente de cristalización utilizado tiene baja toxicidad y bajo residuo, y puede utilizarse mejor en el tratamiento clínico. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510280720 | 2015-05-27 | ||
| PCT/CN2016/083423 WO2016188444A1 (zh) | 2015-05-27 | 2016-05-26 | 一种尿酸转运蛋白抑制剂的钠盐及其结晶形式 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017014319A true MX2017014319A (es) | 2018-03-07 |
Family
ID=57393793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014319A MX2017014319A (es) | 2015-05-27 | 2016-05-26 | Sal sodica de inhibidor de transportador de acido urico y su forma cristalina. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10196361B2 (es) |
| EP (1) | EP3305768B1 (es) |
| JP (1) | JP6738350B2 (es) |
| KR (1) | KR20180006441A (es) |
| CN (1) | CN107001276B (es) |
| AU (1) | AU2016269359B2 (es) |
| BR (1) | BR112017022505A2 (es) |
| CA (1) | CA2984961C (es) |
| CY (1) | CY1123262T1 (es) |
| DK (1) | DK3305768T3 (es) |
| ES (1) | ES2811325T3 (es) |
| HR (1) | HRP20201178T1 (es) |
| HU (1) | HUE051640T2 (es) |
| LT (1) | LT3305768T (es) |
| MX (1) | MX2017014319A (es) |
| PL (1) | PL3305768T3 (es) |
| PT (1) | PT3305768T (es) |
| RS (1) | RS60749B1 (es) |
| RU (1) | RU2719484C2 (es) |
| SI (1) | SI3305768T1 (es) |
| WO (1) | WO2016188444A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017022505A2 (pt) * | 2015-05-27 | 2018-07-17 | Jiangsu Hengrui Medicine Co., Ltd. | sal de sódio de inibidor de transportador de ácido úrico e forma cristalina do mesmo |
| CN108201529B (zh) * | 2016-12-16 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | 一种含有尿酸转运蛋白抑制剂的药物组合物及其制备方法 |
| CN110467571B (zh) * | 2018-05-11 | 2021-02-26 | 江苏恒瑞医药股份有限公司 | 一种制备环烷基甲酸类衍生物或其可药用盐的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SA04250253B1 (ar) * | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| AR051780A1 (es) * | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
| EP2998296B1 (en) * | 2013-05-13 | 2018-03-14 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof |
| BR112017022505A2 (pt) * | 2015-05-27 | 2018-07-17 | Jiangsu Hengrui Medicine Co., Ltd. | sal de sódio de inibidor de transportador de ácido úrico e forma cristalina do mesmo |
-
2016
- 2016-05-26 BR BR112017022505-0A patent/BR112017022505A2/pt not_active Application Discontinuation
- 2016-05-26 KR KR1020177035949A patent/KR20180006441A/ko not_active Application Discontinuation
- 2016-05-26 MX MX2017014319A patent/MX2017014319A/es unknown
- 2016-05-26 CN CN201680003846.8A patent/CN107001276B/zh active Active
- 2016-05-26 US US15/574,328 patent/US10196361B2/en active Active
- 2016-05-26 AU AU2016269359A patent/AU2016269359B2/en active Active
- 2016-05-26 CA CA2984961A patent/CA2984961C/en active Active
- 2016-05-26 EP EP16799331.0A patent/EP3305768B1/en active Active
- 2016-05-26 PT PT167993310T patent/PT3305768T/pt unknown
- 2016-05-26 SI SI201630871T patent/SI3305768T1/sl unknown
- 2016-05-26 DK DK16799331.0T patent/DK3305768T3/da active
- 2016-05-26 RS RS20200924A patent/RS60749B1/sr unknown
- 2016-05-26 JP JP2017555478A patent/JP6738350B2/ja active Active
- 2016-05-26 HU HUE16799331A patent/HUE051640T2/hu unknown
- 2016-05-26 LT LTEP16799331.0T patent/LT3305768T/lt unknown
- 2016-05-26 ES ES16799331T patent/ES2811325T3/es active Active
- 2016-05-26 RU RU2017142996A patent/RU2719484C2/ru active
- 2016-05-26 PL PL16799331T patent/PL3305768T3/pl unknown
- 2016-05-26 WO PCT/CN2016/083423 patent/WO2016188444A1/zh active Application Filing
-
2018
- 2018-10-11 US US16/157,696 patent/US10358424B2/en active Active
-
2020
- 2020-07-28 HR HRP20201178TT patent/HRP20201178T1/hr unknown
- 2020-08-04 CY CY20201100720T patent/CY1123262T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190040015A1 (en) | 2019-02-07 |
| HRP20201178T1 (hr) | 2020-11-13 |
| JP2018515454A (ja) | 2018-06-14 |
| EP3305768A4 (en) | 2019-02-13 |
| ES2811325T3 (es) | 2021-03-11 |
| WO2016188444A1 (zh) | 2016-12-01 |
| RU2017142996A (ru) | 2019-06-27 |
| RS60749B1 (sr) | 2020-10-30 |
| KR20180006441A (ko) | 2018-01-17 |
| PL3305768T3 (pl) | 2020-12-28 |
| JP6738350B2 (ja) | 2020-08-12 |
| US20180134663A1 (en) | 2018-05-17 |
| EP3305768B1 (en) | 2020-07-01 |
| RU2719484C2 (ru) | 2020-04-17 |
| CN107001276A (zh) | 2017-08-01 |
| CA2984961C (en) | 2023-08-01 |
| US10358424B2 (en) | 2019-07-23 |
| EP3305768A1 (en) | 2018-04-11 |
| RU2017142996A3 (es) | 2019-11-20 |
| AU2016269359B2 (en) | 2020-02-06 |
| CN107001276B (zh) | 2020-03-13 |
| DK3305768T3 (da) | 2020-08-10 |
| PT3305768T (pt) | 2020-08-03 |
| US10196361B2 (en) | 2019-02-05 |
| LT3305768T (lt) | 2020-08-25 |
| BR112017022505A2 (pt) | 2018-07-17 |
| CY1123262T1 (el) | 2021-12-31 |
| SI3305768T1 (sl) | 2020-10-30 |
| AU2016269359A1 (en) | 2017-11-23 |
| HUE051640T2 (hu) | 2021-03-01 |
| CA2984961A1 (en) | 2016-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500169A1 (en) | Polymorph of syk inhibitors | |
| PH12015501585A1 (en) | Manufacturing process for pyrimidine derivatives | |
| CY1123262T1 (el) | Αναστολεας metaφopea aλatoς natpioy oypikoy oξeoς kai kpyσtaλλikh mopφh aytoy | |
| MX2018014374A (es) | Tiofeno, método de fabricación y aplicación farmacéutica del mismo. | |
| NZ738836A (en) | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid | |
| TW201613931A (en) | Form crystal of bisulfate of janus kinase (JAK) inhibitor and preparation method thereof | |
| MX2020000886A (es) | Inhibidores de ror gamma. | |
| MX2019011783A (es) | Inhibidores de ip6k. | |
| MX2017011392A (es) | P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su metodo de preparacion. | |
| WO2016142819A3 (en) | Novel process for the preparation of ranolazine | |
| MX2019014078A (es) | Inhibidor de urat1 para promover la excresion de acido urico. | |
| MX2021002896A (es) | Proceso para preparar 1-(3,5-diclorofenil)-2,2,2-trifluoroetanona y sus derivados. | |
| PH12017500435A1 (en) | A salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof | |
| EP3272734A8 (en) | Ahu377 crystal form, preparation method and use thereof | |
| TW201612188A (en) | The L-proline complex, monohydrate and crystal of a sodium-glucose contransporter 2 inhibitor | |
| MX2016015577A (es) | La teobromina o sus derivados para el tratamiento o la prevencion de la litiasis renal. | |
| WO2012150183A8 (en) | Crystalline sodium salt of an hiv integrase inhibitor | |
| PH12018501046B1 (en) | Crystal of monovalent cation salt of 3-hydroxyisovaleric acid and process for producing the crystals | |
| TW201613940A (en) | High purity crystal of activated blood coagulation factor Xa (FXa) inhibitor | |
| TH176475A (th) | ผลึกของ โลหะแอลคาไล n-อะซีติลนิวรามิเนท แอนไฮเดรท และกรรมวิธีการผลิตสิ่งนั้น | |
| TH168948B (th) | สารกระทำแอนติ-ไตรโคไฟตอน ที่เป็นผลึกและกระบวนการเตรียมสารเหล่านี้ | |
| NZ624622A (en) | Manufacturing process for pyrimidine derivatives | |
| PL415140A1 (pl) | Kryształ europu (III) z benzoesanem tetrabutyloamoniowym oraz sposób jego wytwarzania | |
| TN2013000094A1 (en) | Manufacturing process for pyrimidine derivatives | |
| MX347693B (es) | Cristal del acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluorop irrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidr oquinolin-3-carboxilico. |